Allogeneic G-natural killer cell therapy(Indapta Therapeutics/Stanford University/University of California San Francisco)

N/A

Report date: 2022/09/06 18:03:19

Base Information

Drug NameAllogeneic G-natural killer cell therapy(Indapta Therapeutics/Stanford University/University of California San Francisco)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacements
TargetsNot applicable
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesStanford UniversityUniversity Of California, San Francisco Fresno
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California, San Francisco FresnoStanford University
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A